SurVaxM
- Generic Name
- SurVaxM
- Drug Type
- Biotech
- CAS Number
- 2416847-76-0
- Unique Ingredient Identifier
- HK7BJ56KSP
SurVaxM Glioblastoma Trial Advances Following Positive Interim Analysis
• MimiVax's Phase 2b SURVIVE trial for SurVaxM in newly diagnosed glioblastoma patients has successfully passed its first interim analysis, allowing the study to continue as planned.
• The trial evaluates SurVaxM in combination with standard-of-care treatment across 11 major U.S. Cancer Centers, targeting the survivin protein present in most glioblastomas.
• The fully enrolled study aims to determine if adding SurVaxM to standard treatment (resection, radiation/chemotherapy) improves outcomes for glioblastoma patients.
Renewed Hope for Glioblastoma: Novel Therapies Show Promise After Decades of Stagnation
• New therapeutic approaches, including small molecules, cell therapies, and vaccines, are revitalizing glioblastoma research after 20 years of limited progress.
• Merck's acquisition of Modifi Biosciences and Kazia Therapeutics' paxalisib are leading the charge with innovative small molecule therapies targeting DNA repair and PI3K pathways, respectively.
• CAR T-cell therapies targeting EGFR and interleukin-13 receptor alpha 2, along with vaccines like SurVaxM, are showing early promise in shrinking tumors and improving survival.
• The glioblastoma market is projected to grow to $5.7 billion by 2033, driven by targeted therapies and immunotherapies, signaling increased investment and innovation in the field.
Roswell Park's Brain Cancer Vaccine, SurVaxM, Shows Promise in Pediatric Brain Tumor Trial
• SurVaxM, a brain cancer vaccine developed at Roswell Park, has shown promising results in adults by doubling survival time in glioblastoma patients.
• A pilot clinical trial is underway to evaluate SurVaxM's safety and efficacy in children and young adults with high-risk brain tumors, including DIPG.
• The vaccine targets survivin, a protein crucial for tumor cell survival, and has demonstrated mild side effects in adult trials by stimulating the immune system.
• Researchers are exploring SurVaxM's potential effectiveness against other cancers, with ongoing trials for multiple myeloma and neuroendocrine tumors.
Promising Brain Cancer Vaccine SurVaxM Enters Phase 2B Trial for Newly Diagnosed Glioblastoma
• Roswell Park Comprehensive Cancer Center has launched the SURVIVE trial, a phase 2B randomized study evaluating SurVaxM immunotherapy in 265 newly diagnosed glioblastoma patients.
• Previous phase II results showed remarkable outcomes with SurVaxM, with 96.8% of patients progression-free at 6 months and 93.5% surviving at 12 months, compared to 65% with standard care.
• SurVaxM targets survivin, a protein that helps cancer cells survive, and will be tested across 15 sites in the US and China as researchers seek better options for this aggressive brain cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath